So how much are we really talking about?Market scale:
Can the Actipatch be used to treat inflammation from tendonitus and how big is the chronic inflammation market
The global chronic inflammatory disease (CID) market (covering conditions like arthritis, inflammatory bowel disease, chronic venous insufficiency, and others) is estimated at hundreds of billions of USD annually. For example, the arthritis segment alone is valued at over $200 billion globally【industry reports】.
The chronic inflammation treatment market (including drugs, devices, and services) is often cited in the $300–$500 billion USD range worldwide, depending on scope and inclusion of overlapping conditions【industry analyses】.
In the U.S., chronic inflammatory conditions account for a significant share of the $1–$1.5 trillion annual healthcare spend, with billions allocated to anti‑inflammatory therapies.
Bottom line: ActiPatch is not FDA‑cleared specifically for tendinitis inflammation, but its PSWT technology is theorized to influence inflammatory pathways. It can be used as an adjunct for musculoskeletal pain, including conditions like tendinitis, but should not replace standard anti‑inflammatory treatments.
Chronic Inflammation Market Size
The chronic inflammation market is not a single, standardized product category, but it is a broad segment encompassing:
Pharmaceuticals: NSAIDs, corticosteroids, biologic agents, and targeted anti‑inflammatory drugs.
Devices & therapies: Physical therapy, neuromodulation devices, and other non‑drug interventions.
Consumer health products: Supplements, topical agents, and home‑based therapies.
Better load up!
Can the Actipatch be used to treat inflammation from tendonitus and how big is the chronic inflammation market
The global chronic inflammatory disease (CID) market (covering conditions like arthritis, inflammatory bowel disease, chronic venous insufficiency, and others) is estimated at hundreds of billions of USD annually. For example, the arthritis segment alone is valued at over $200 billion globally【industry reports】.
The chronic inflammation treatment market (including drugs, devices, and services) is often cited in the $300–$500 billion USD range worldwide, depending on scope and inclusion of overlapping conditions【industry analyses】.
In the U.S., chronic inflammatory conditions account for a significant share of the $1–$1.5 trillion annual healthcare spend, with billions allocated to anti‑inflammatory therapies.
Bottom line: ActiPatch is not FDA‑cleared specifically for tendinitis inflammation, but its PSWT technology is theorized to influence inflammatory pathways. It can be used as an adjunct for musculoskeletal pain, including conditions like tendinitis, but should not replace standard anti‑inflammatory treatments.
Chronic Inflammation Market Size
The chronic inflammation market is not a single, standardized product category, but it is a broad segment encompassing:
Pharmaceuticals: NSAIDs, corticosteroids, biologic agents, and targeted anti‑inflammatory drugs.
Devices & therapies: Physical therapy, neuromodulation devices, and other non‑drug interventions.
Consumer health products: Supplements, topical agents, and home‑based therapies.
Better load up!
2
